Cardiovascular Disease Risk Reduction and Body Mass Index

Purpose of Review Anti-hypertensive and lipid lowering therapy addresses only half of the cardiovascular disease risk in patients with body mass index > 30 kg/m(2), i.e., obesity. We examine newer aspects of obesity pathobiology that underlie the partial effectiveness of anti-hypertensive lipid lowering therapy for the reduction of cardiovascular disease risk in obesity. Recent Findings Obesity-related insulin resistance, vascular endothelium dysfunction, increased sympathetic nervous system/renin-angiotensin-aldosterone system activity, and glomerulopathy lead to type 2 diabetes, coronary atherosclerosis, and chronic disease kidney disease that besides hypertension and dyslipidemia increase cardiovascular disease risk. Obesity increases cardiovascular disease risk through multiple pathways. Optimal reduction of cardiovascular disease risk in patients with obesity is likely to require therapy targeted at both obesity and obesity-associated conditions.

Automated summary

Anti-hypertensive and lipid lowering therapy only addresses half of the cardiovascular disease risk in obese patients. This review examines newer aspects of obesity pathobiology that explain the partial effectiveness of these therapies in reducing cardiovascular disease risk in obesity.